×

Traders expecting an 80% move for this hot biotech stock in the next month

Biotech stocks are on fire this year, surging nearly 24 percent, and a key event this week could spark a massive move in one name that's already up more than 100 percent.

Biotech company Axovant is expected to release important data at the end of September, and the options market is implying a more than 80 percent move in either direction for the stock.

"Data is supposed to come at the end of this month. The next listed options is listed in October," Dan Nathan of RiskReversal said Thursday on CNBC's "Fast Money."

Nathan noted that Axovant shares are trading around $26, so the at-the-money straddle, or simply the call price plus the put price, is $22. This means that the options market is expecting a move in the stock to go as high as $48 or as low as $4 by October expiration.

"Now obviously the much better trade is to the upside, because we know the stock could go to infinity and it could only go to zero [on the downside]. ... At the end of the day, it's a pretty interesting setup," Nathan explained.

Axovant shares were trading more than 1 percent lower at the $25.79 range midday Friday.

Options Action Newsletter:

Sign up to receive exclusive Options Action content. Each month you'll receive an exclusive message from host Melissa Lee and insight directly from one of the members of our Options Action panel. Keep your pulse on the market with the Options Action newsletter.

Please enter a valid email address
To learn more about how we use your information, please read our Privacy Policy.

Latest Video

Tutorials

Host Bio

  • Melissa Lee

    Melissa Lee is the host of CNBC's “Fast Money” and “Options Action.”

Options Action Traders

From Our Sponsor

Options Action Newsletter:

Sign up to receive exclusive Options Action content. Each month you'll receive an exclusive message from host Melissa Lee and insight directly from one of the members of our Options Action panel. Keep your pulse on the market with the Options Action newsletter.

Please enter a valid email address
To learn more about how we use your information, please read our Privacy Policy.